DMD patient urges FDA confirmation to prioritize rare disease access

A 25-year-old living with Duchenne muscular dystrophy has called on the Senate to confirm Dr. Heidi Overton as Food and Drug Administration commissioner, arguing that the next agency leader must treat patients as partners in their own survival rather than passive observers. The individual, who recently turned 25, stated that people with the progressive disease are not expected to see another birthday after this one, making the regulatory environment a matter of immediate life and death for the 30 million Americans living with rare diseases.

The patient emphasized that the FDA commissioner's decisions determine how many treatment options are available and how much time remains to use them. While acknowledging the necessity of scientific rigor and clinical trials, the individual questioned why a regulator in Washington holds the final word on risk acceptance when both the patient and their physician understand the potential benefits of an investigational treatment. This perspective aligns with the Right to Try Act, signed into law by President Trump in 2018, which allows patients with life-threatening conditions to access unapproved treatments when approved options are exhausted.

Senator Ron Johnson and Representative Diana Harshbarger have introduced legislation known as Right to Try 2.0, aiming to extend this patient-centered philosophy to individualized treatments that do not fit traditional approval models. The patient argued that the FDA should not wait for Congress to force a more collaborative approach, noting that the agency's accelerated approval pathway was designed to prevent life-threatening delays for serious diseases. The FDA has already utilized this pathway for multiple treatments for Duchenne muscular dystrophy.

For those with Duchenne, waiting is never neutral, as each year can result in further loss of strength and independence. The patient noted that their brother, who also has the disease, has faced significant barriers in accessing existing treatments, including the burden of traveling hours away from home for multiyear clinical trials. The individual advocated for an FDA that works alongside physicians and rare-disease experts to reduce these logistical and regulatory hurdles.

In a specific recommendation, the patient expressed hope that Dr. Houman Hemmati would be appointed as deputy commissioner. Hemmati has a career in biotech focused on building treatments for rare and degenerative diseases rather than regulating them from outside. The patient acknowledged the potential criticism regarding personal relationships but maintained that Hemmati's direct experience with the disease and his professional background make him a suitable candidate to lead a more patient-centered agency culture.